Baidu
map

Nat Commun:抗药性H7N9流感病毒有高度传播性

2014-01-14 Nature中文网 Nature中文网

新出现的H7N9流感病毒的一个突变能使其对惟一一类对该病毒有活性的药物产生抵抗力,而不会影响其在动物中传播的能力。发表在本期Nature Communications上一篇研究论文中的这一发现表明,与季节性流感不同的是,抗药性H7N9病毒能够与非抗药性H7N9病毒同样高效地在动物中复制。 Nicole Bouvier及同事对从中国一位患者身上分离出的突变的H7N9病毒进行了分析,以了解它对药物的

新出现的H7N9流感病毒的一个突变能使其对惟一一类对该病毒有活性的药物产生抵抗力,而不会影响其在动物中传播的能力。发表在本期Nature Communications上一篇研究论文中的这一发现表明,与季节性流感不同的是,抗药性H7N9病毒能够与非抗药性H7N9病毒同样高效地在动物中复制。【原文下载】

Nicole Bouvier及同事对从中国一位患者身上分离出的突变的H7N9病毒进行了分析,以了解它对药物的抵抗力和它的感染力。他们发现,该病毒对抗病毒药物Oseltamivir(亦称为Tamiflu)有很强抵抗力。另外,它也能与未突变的H7N9病毒同样高效地感染培养的人细胞和在实验动物之间传播。这是不同寻常的,因为我们知道,当季节性流感病毒产生抗药性时,这对病毒本身来说通常是有代价的,代价就是其在宿主之间传播和在它们体内生长的能力会降低。

H7N9流感是今年早些时候在中国出现的,迄今已造成超过130个人类感染病例。由于还没有针对这种流感的疫苗,所以目前抗病毒药物是控制H7N9感染的惟一办法。我们知道,抗病毒药物治疗会导致流感病毒产生抗药性,而这项研究进一步说明了对H7N9流感病毒感染慎用抗病毒药物的必要性。

原文出处:

Hai R, Schmolke M, Leyva-Grado VH, Thangavel RR, Margine I, Jaffe EL, Krammer F, Solórzano A, García-Sastre A, Palese P, Bouvier NM.Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.Nat Commun. 2013 Dec 10;4:2854. doi: 10.1038/ncomms3854.【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1907357, encodeId=1d1d190e35720, content=<a href='/topic/show?id=a6c425886a9' target=_blank style='color:#2F92EE;'>#传播性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25886, encryptionId=a6c425886a9, topicName=传播性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sun Oct 19 02:49:00 CST 2014, time=2014-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879850, encodeId=1c3018e98502e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 06 07:49:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086676, encodeId=043b20866e6a6, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Dec 25 07:49:00 CST 2014, time=2014-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477439, encodeId=f08e14e74397f, content=<a href='/topic/show?id=9f7d8411fc' target=_blank style='color:#2F92EE;'>#H7N9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8411, encryptionId=9f7d8411fc, topicName=H7N9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1f27379114, createdName=ms117281293605716, createdTime=Thu Jan 16 01:49:00 CST 2014, time=2014-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495362, encodeId=2d8c14953624e, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Jan 16 01:49:00 CST 2014, time=2014-01-16, status=1, ipAttribution=)]
    2014-10-19 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1907357, encodeId=1d1d190e35720, content=<a href='/topic/show?id=a6c425886a9' target=_blank style='color:#2F92EE;'>#传播性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25886, encryptionId=a6c425886a9, topicName=传播性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sun Oct 19 02:49:00 CST 2014, time=2014-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879850, encodeId=1c3018e98502e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 06 07:49:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086676, encodeId=043b20866e6a6, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Dec 25 07:49:00 CST 2014, time=2014-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477439, encodeId=f08e14e74397f, content=<a href='/topic/show?id=9f7d8411fc' target=_blank style='color:#2F92EE;'>#H7N9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8411, encryptionId=9f7d8411fc, topicName=H7N9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1f27379114, createdName=ms117281293605716, createdTime=Thu Jan 16 01:49:00 CST 2014, time=2014-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495362, encodeId=2d8c14953624e, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Jan 16 01:49:00 CST 2014, time=2014-01-16, status=1, ipAttribution=)]
    2014-10-06 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1907357, encodeId=1d1d190e35720, content=<a href='/topic/show?id=a6c425886a9' target=_blank style='color:#2F92EE;'>#传播性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25886, encryptionId=a6c425886a9, topicName=传播性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sun Oct 19 02:49:00 CST 2014, time=2014-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879850, encodeId=1c3018e98502e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 06 07:49:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086676, encodeId=043b20866e6a6, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Dec 25 07:49:00 CST 2014, time=2014-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477439, encodeId=f08e14e74397f, content=<a href='/topic/show?id=9f7d8411fc' target=_blank style='color:#2F92EE;'>#H7N9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8411, encryptionId=9f7d8411fc, topicName=H7N9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1f27379114, createdName=ms117281293605716, createdTime=Thu Jan 16 01:49:00 CST 2014, time=2014-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495362, encodeId=2d8c14953624e, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Jan 16 01:49:00 CST 2014, time=2014-01-16, status=1, ipAttribution=)]
    2014-12-25 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1907357, encodeId=1d1d190e35720, content=<a href='/topic/show?id=a6c425886a9' target=_blank style='color:#2F92EE;'>#传播性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25886, encryptionId=a6c425886a9, topicName=传播性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sun Oct 19 02:49:00 CST 2014, time=2014-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879850, encodeId=1c3018e98502e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 06 07:49:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086676, encodeId=043b20866e6a6, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Dec 25 07:49:00 CST 2014, time=2014-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477439, encodeId=f08e14e74397f, content=<a href='/topic/show?id=9f7d8411fc' target=_blank style='color:#2F92EE;'>#H7N9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8411, encryptionId=9f7d8411fc, topicName=H7N9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1f27379114, createdName=ms117281293605716, createdTime=Thu Jan 16 01:49:00 CST 2014, time=2014-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495362, encodeId=2d8c14953624e, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Jan 16 01:49:00 CST 2014, time=2014-01-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1907357, encodeId=1d1d190e35720, content=<a href='/topic/show?id=a6c425886a9' target=_blank style='color:#2F92EE;'>#传播性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25886, encryptionId=a6c425886a9, topicName=传播性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sun Oct 19 02:49:00 CST 2014, time=2014-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879850, encodeId=1c3018e98502e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 06 07:49:00 CST 2014, time=2014-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086676, encodeId=043b20866e6a6, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Dec 25 07:49:00 CST 2014, time=2014-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477439, encodeId=f08e14e74397f, content=<a href='/topic/show?id=9f7d8411fc' target=_blank style='color:#2F92EE;'>#H7N9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8411, encryptionId=9f7d8411fc, topicName=H7N9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1f27379114, createdName=ms117281293605716, createdTime=Thu Jan 16 01:49:00 CST 2014, time=2014-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495362, encodeId=2d8c14953624e, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Jan 16 01:49:00 CST 2014, time=2014-01-16, status=1, ipAttribution=)]
    2014-01-16 songbq

相关资讯

J Infect :H7N9禽流感死亡病例分析

2013年3月31日,上海首次报道确诊人感染H7N9禽流感病例,约2个月后,国内实验室确诊的H7N9感染总人数达到了132例,其中37例死亡。浙江省是H7N9感染率最高的省份之一,从2013年4月1日第1例确诊病例至2013年5月31日,共有实验室确诊病例46例,其中10例死亡,病死率为21.73%。 人感染H7N9禽流感的高死亡率引起中国各方的高度关注,造成高死亡率的原因尚不明确。来自浙江省疾

CMI:H7N9禽流感患者免疫反应和临床结局相关影响因素

进入秋冬季后,H7N9病毒又卷土重来。浙江,广东相继报告多例人感染H7N9禽流感病例。关于这一新病毒引起的机体的免疫反应和该疾病的临床特征还未知。来自上海市公共卫生临床中心的研究人员对该中心收治的18例病人的临床特征和机体的免疫反应进行研究分析。结果认为,病人体内的高病毒载量和强烈的细胞因子风暴是人感染H7N9禽流感重要的发病机制。该研究发表在 2013年12月18日的《临床微生物和感染》(cli

卫计委公布2013年中国卫生计生十大新闻

7日上午,国家卫生计生委举行新闻发布会。国家卫生和计划生育委员会宣传司司长、新闻发言人毛群安介绍了2013年中国卫生计生十大新闻。 这十大新闻是:国家卫生和计划生育委员会成立。党中央国务院对深化医改进行全面部署。坚持计划生育基本国策,启动实施单独两孩政策。妥善应对H7N9疫情等突发公共卫生事件。进一步扩大卫生援外合作,中国援外医疗队派遣50周年系列纪念活动举办。深入开展党

Lancet:盘点2013年医疗健康中重大进展

本文主要就2013年上头条的医疗事件进行一个汇总,主要包括一些新旧病毒、大脑研究项目以及台风等等。  英国全民医疗保健体制(NHS)危机  2013年4月1日,英国《健康和社会保健方案》正式生效,但遭到了大多数健康专业人士的反对,反对者认为,一方面,市场力量的释放,将会破坏国民卫生服务体系的稳定性,从而不利于居民获得连续性医疗卫生服务。另一方面,信托机构的撤销,使得原来

深圳活禽市场检出H7N9病毒阳性

广东省卫生计生委11日发布消息称,深圳市龙岗区活禽市场环境标本检出H7N9禽流感病毒核酸阳性。专家评估认为,广东省发生散发人感染H7N9禽流感病例风险极高。 12月10日,广东省和深圳市防控人感染H7N9禽流感联合工作组在对深圳市活禽市场环境禽流感病毒污染的监测中,共采集13个活禽市场70份环境标本,其中,龙岗区两个活禽市场检出3份H7N9禽流感病毒核酸阳性(1份来

PNAS:对H7N9的细胞介导免疫具有种族差异

日前,来自澳大利亚墨尔本大学等机构的科学家发现,由于参与细胞介导免疫应答的一个蛋白质复合体的遗传差异,人们对 2013 年 2 月出现的 H7N9 流感病毒启动一种细胞介导免疫的能力可能不同。【原文下载】 人类此前没有遇到过 H7N9 病毒,因此缺乏抵抗这种病毒的保护性抗体。动物和人类研究显示,在缺乏抵抗一种新流感毒株的保护性抗体的情况下,此前产生的抵抗其他流感毒株的

Baidu
map
Baidu
map
Baidu
map